Background {#Sec1}
==========

The treatment of knee OA is currently restricted to management of pain and function with low-to-moderate efficacy. The potential of a combined beneficial effect on joint structure and symptoms in OA as a result of treatment with several pharmacologic compounds has been investigated \[[@CR1]--[@CR4]\]. However, none of these agents has been shown to have unequivocally beneficial effects on structural characteristics that also translate into clinical benefit \[[@CR5]\]. Many studies have focused on use of anticatabolic agents to delay progression \[[@CR5]\]. An alternative approach is to stimulate cartilage development and repair. Sprifermin (recombinant human fibroblast growth factor 18; rhFGF18) binds to and specifically activates fibroblast growth factor receptor 3 (FGFR-3) in cartilage to promote chondrogenesis and cartilage matrix production in vitro \[[@CR6]\]. Preclinical data have shown that sprifermin stimulates chondrocyte proliferation, cartilage matrix formation, and cartilage repair in vitro and in vivo \[[@CR6], [@CR7]\]. Recently, the results of a randomized, double-blind, placebo-controlled phase 1b clinical trial of sprifermin in knee OA were reported \[[@CR8]\]. In that trial, no statistically significant response was seen in the primary structural endpoint, the central medial tibio-femoral compartment cartilage thickness on quantitative MRI (qMRI) \[[@CR8]\]. However, pre-specified secondary structural efficacy endpoints, such as loss of total and lateral tibio-femoral cartilage thickness, showed statistically significant dose-dependent effects. Given the close interaction of the different tissues on a local level within the joint and its relevance to structural progression \[[@CR9]\], changes in cartilage surface morphology may also be associated with an impact on the subchondral bone and other joint structures.

For these reasons a post-hoc investigation taking into account changes in multiple joint tissues based on semi-quantitative scoring and using advanced analytic approaches was conducted. The aim of this post-hoc analysis was to determine effects of sprifermin on semi-quantitative MRI (sqMRI) features of knee OA compared with placebo treatment.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Details of study design and patient inclusion have been reported \[[@CR8]\]. In brief, in this multicenter, randomized, double blind, placebo-controlled trial, (ClinicalTrials.gov identifier: NCT01033994), sprifermin was evaluated as a single treatment and as a multiple-dose regimen with three doses of either 10 μg, 30 μg, or 100 μg with 21, 42 and 63 patients respectively, and matched placebo groups of 7, 14 and 21 patients, respectively. Patients were aged ≥40 years, had an established diagnosis of primary tibio-femoral knee OA according to American College of Rheumatology clinical and radiologic criteria, with Kellgren-Lawrence (KL) grade 2 or 3 disease in the target knee \[[@CR10]\]. Altogether 477 patients were screened and 192 were randomized (24 to the single-dose cohorts and 168 to the multiple-dose cohorts. All patients in the single-dose cohorts received treatment with the study drug and completed the trial. All patients in the multiple-dose cohorts received ≥1 dose of study medication, with 168 forming the modified intent-to-treat population; 156 (92.9 %) completed the trial.

Similar to the recently reported post-hoc analysis on quantitative cartilage parameters \[[@CR11]\], the current sqMRI analysis focuses on subjects with baseline and 12 month data in the cohort that received sprifermin 100 μg (*n* = 57) (since this was the dosing regimen on which significant drug efficacy was observed \[[@CR8]\]), and in those who were randomized, in parallel, to receive matching placebo (*n* = 18). Since this multicenter trial enrolled cohorts sequentially using a dose-ascending approach across 30 sites on multiple continents \[[@CR11]\], a comparison of the 100 μg subgroup with a combined placebo subgroup incorporating all dosages (*n* = 42) was not warranted. The detailed flow-chart of inclusion of the current analysis is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Detailed flow-chart of subject inclusion to the 100 μg subgroup

Primary end points and assessments {#Sec4}
----------------------------------

The primary efficacy end point was the longitudinal change from baseline in central medial tibio-femoral compartment cartilage thickness at 6 months and 12 months, as assessed using qMRI \[[@CR8]\].

Secondary end points and assessments {#Sec5}
------------------------------------

Secondary imaging end points included total and compartmental femorotibial cartilage thickness and volume as assessed by qMRI, measurement of joint space width by fixed-flexion weight-bearing radiography, and assessment of bone marrow lesions (BMLs), cartilage, menisci, osteophytes, effusion, and synovitis by sqMRI using the modified Whole-Organ Magnetic Resonance Imaging Score (WORMS) at baseline, 3, 6, and 12 months follow-up \[[@CR12]\].

MRI acquisition {#Sec6}
---------------

MRIs were acquired using 1.5 T or 3 T systems. Axial, coronal, and sagittal intermediate-weighted turbo or fast spin--echo fat-suppressed sequences were used for semiquantitative whole joint assessment of structural tissue pathology, with identical parameters, software and hardware used at baseline and follow-up. Image parameters were as follows: slice thickness 3.0 mm, in-plane resolution 0.55 × 0.55 mm, repetition time 3,600--4,000 msec, and echo time 30--40 msec. In addition the double-oblique coronal spoiled gradient-recalled sequences with fat suppression or water excitation that were acquired for cartilage thickness determination using quantitative MRI were considered for sqMRI assessment with the following acquisition paramaters: contiguous slice thickness 1.5 mm, in-plane resolutions 0.23 × 0.23 mm to 0.32 × 0.32 mm, repetition time 18--50 msec, echo time 6.5--14 msec, flip angle 15--20°.

MRI interpretation {#Sec7}
------------------

Four musculoskeletal radiologists (FWR, AG, MDC, MDM), with 7--16 years experience in standardized sqMRI assessment of knee OA, graded cartilage status, BMLs, osteophytes, effusion, synovitis and meniscal morphology according to the WORMS system \[[@CR12]\] with blinding to treatment, radiographic OA grade and clinical data. In addition to the published WORMS scale medial and lateral meniscal extrusion was assessed on the coronal plane according to previous publications \[[@CR13], [@CR14]\] and graded as follows: 0 = no meniscal extrusion,1 = extrusion \< 50 %, 2 = extrusion ≥ 50 %. Baseline and follow-up MRIs were presented sequentially, with the chronological acquisition order known to the readers. The four readers assessed the images independently with an equal number of examinations assigned to each reader.

Statistical analysis {#Sec8}
--------------------

Statistical analyses were performed using SAS software (version 9.1; SAS Institute). Included in the current analysis were patients from the 100 μg and matched placebo subgroups with complete MRI datasets with all features and subregions scorable. Analyses included multi-dimensional assessment: (a) A delta-subregional approach was applied, which adds the *number of subregions* (total of 14 articular subregions for cartilage and BMLs on a knee level, 5 subregions each for the medial and lateral tibio-femoral \[MTFJ, LTFJ\] and 4 subregions for the patello-femoral \[PFJ\] compartment) showing worsening (\>0), no change (0) or improvement (\<0). As an example, 5 subregions showing worsening, 7 subregions showing improvement and 3 subregions showing no change will result in a delta-subregion change of −2. (b) In addition, a delta-sum approach was used, which adds the absolute *scores of all subregions* combined per compartment or for the whole knee. Analyses were performed on a whole knee level and separately for MTFJ, LTFJ and PFJ compartments for all subgroups. Mann--Whitney − Wilcoxon tests assessed differences between treatment groups. In sensitivity analysis adjusting for baseline values, analysis of covariance (ANCOVA) on ranked baseline and post baseline values was performed. *P*-values were not adjusted for multiple testing.

Results {#Sec9}
=======

In regard to baseline demographic characteristics the 100 μg and matched placebo subgroup were comparable without statistically significant differences in regard to age, gender, BMI, KL grade and time since onset of OA. The detailed patient demographics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Patient demographics100 μg group\
(*n* = 57)Matched placebo group\
(*n* = 18)Age, mean (standard deviation)61.2 (9.1)60.9 (6.9)Sex, no. (%) female39 (68.4)12 (66.7)Body mass index (standard deviation)30.5 (5.0)31.5 (5.3)Kellgren-Lawrence grade 3 (%)29 (50.9)11 (61.1)Time since onset of osteoarthritis, years (standard deviation)7.1 (5.4)7.4 (3.7)

For change in cartilage surface morphology from baseline to 12 months, statistically significant differences with less worsening in the treatment group were observed in the PFJ (delta-sum approach; treatment 0.05, 95 % CI (−0.06, 0.17) vs. placebo 0.44, 95 % CI (−0.18, 1.06), *p* = 0.048; delta-subregional approach; treatment (0.02 95 % CI (−0.04, 0.08) vs. placebo 0.22, 95 % CI (−0.05, 0.49), *p* = 0.046). Although baseline values were statistically different, after adjusting for baseline in ANCOVA sensitivity analysis, results remained statistically significant at a significance level of 0.05.

For change in BMLs from baseline to 12 months only, no significant findings were seen for either treatment or placebo groups using both analytic approaches.

The details of the baseline to 12 months analyses for cartilage and BMLs are presented in Table [2](#Tab2){ref-type="table"}.Table 2Cartilage morphology and bone marrow lesion ─ baseline and change from baseline to 12 monthsCartilage morphologyBone marrow lesion100 μg cohort (*n* = 57)\
mean (95 % CI)Matched placebo (*n* = 18)\
mean (95 % CI)*p* - value100 μg cohort (*n* = 56)\
mean (95 % CI)Matched placebo (*n* = 18)\
mean (95 % CI)*p* - valueWhole kneeBaseline21.1 (17.2, 25.0)30.0 (22.0,37.9)0.040\*3.3 (2.5, 4.1)3.3 (1.4, 5.2)0.642Delta sum0.42 (0.00, 0.84)0.94 (−0.34, 2.23)0.362−0.20 (−0.67, 0.28)0.22 (−0.62, 1.07)0.237Delta subregion0.19 (−0.01, 0.40)0.44 (−0.24, 1.13)0.371−0.23 (−0.60, 0.14)0.22 (−0.43, 0.87)0.113LTFJBaseline4.5 (2.6, 6.4)7.6 (3.8, 11.5)0.019\*0.7 (0.3, 1.1)0.7 (0.0, 1.4)0.981Delta sum0.07 (−0.16, 0.30)0.17 (−0.09, 0.42)0.3420.04 (−0.16, 0.23)0.11 (−0.05, 0.27)0.242Delta subregion0.05 (−0.07, 0.18)0.11 (−0.05, 0.27)0.3490.04 (−0.13, 0.20)0.17 (−0.02, 0.36)0.107MTFJBaseline9.3 (7.2, 11.5)11.5 (7.3, 15.8)0.3521.6 (1.1, 2.2)1.1 (0.3, 1.9)0.418Delta sum0.30 (−0.04, 0.64)0.33 (−0.28, 0.95)0.690−0.11 (−0.50, 0.28)0.11 (−0.52, 0.75)0.469Delta subregion0.12 (−0.03, 0.27)0.11 (−0.27, 0.49)0.712−0.13 (−0.40, 0.15)0.06 (−0.34, 0.45)0.510PFJBaseline7.3 (5.6., 9.1)10.8 (7.5, 14.1)0.038\*1.0 (0.5, 1.5)1.5 (0.1, 2.9)1.000Delta sum0.05 (−0.06, 0.17)0.44 (−0.18, 1.06)0.048\*−0.13 (−0.34, 0.09)0.00 (−0.38, 0.38)0.368Delta subregion0.02 (−0.04, 0.08)0.22 (−0.05, 0.49)0.046\*−0.14 (−0.34, 0.06)0.00 (−0.38, 0.38)0.352*CI* confidence interval, *LTFJ* lateral tibio-femoral joint (includes 5 subregions), *MTFJ* medial tibio-femoral joint (includes 5 subregions), *PFJ* patello-femoral joint (includes 4 subregions). Possible score range for each subregion at baseline and 12-month is 0--3 and 0--6 for bone marrow lesion and cartilage morphology, respectively\*Statistically significant at *p* ≤ 0.05

For BMLs, in post-hoc evaluation, all interim visits were analyzed in a non-preplanned time frame. Statistically significant changes in BMLs in favor of the treatment group were observed for the whole knee from 6 to 12 months (delta-subregional approach; treatment −0.14, 95 % CI (−0.48, 0.19) vs. placebo 0.44, 95 % CI (−0.15, 1.04), *p* = 0.042), and were borderline for the LTFJ (delta-sum approach; treatment −0.13, 95 % CI (−0.39, 0.14) vs. placebo 0.22, 95 % CI (−0.10, 0.54), *p* = 0.062; delta-subregion approach: −0.05, 95 % CI (−0.27, 0.16) vs placebo 0.22, 95 % CI (−0.10, 0.54), *p* = 0.064). The detailed BML analyses for the different intervals are presented in Table [3](#Tab3){ref-type="table"}. For all other analyzed parameters including meniscus, osteophytes, effusion-synovitis and Hoffa-synovitis, no significant changes from baseline to 12 months or between groups were observed.Table 3Bone marrow lesion changes between interim visits100 μg cohort (*n* = 56) Mean (95 % CI)Matched placebo (*n* = 18) Mean (95 % CI)*p* - valueWhole kneeBaseline3.3 (2.5, 4.1)3.3 (1.4, 5.2)0.642Delta sum 0 to 3 months−0.02 (−0.38, 0.34)−0.17 (−0.85, 0.52)0.682 3 to 6 months−0.04 (−0.41, 0.34)−0.06 (−0.37, 0.26)0.933 6 to 12 months−0.14 (−0.54, 0.26)0.44 (−0.15, 1.04)0.054Delta subregion 0 to 3 months0.02 (−0.28, 0.32)−0.22 (−0.87, 0.43)0.597 3 to 6 months−0.05 (−0.37, 0.27)−0.06 (−0.37, 0.26)0.911 6 to 12 months−0.14 (−0.48, 0.19)0.44 (−0.15, 1.04)0.042\*LTFJBaseline0.7 (0.3, 1.1)0.7 (0.0, 1.4)0.981Delta sum 0 to 3 months0.04 (−0.12, 0.19)0.00 (−0.17, 0.17)0.859 3 to 6 months0.13 (−0.11, 0.36)−0.11 (−0.40, 0.18)0.155 6 to 12 months−0.13 (−0.39, 0.14)0.22 (−0.10, 0.54)0.062Delta subregion 0 to 3 months0.04 (−0.12, 0.19)0.00 (−0.17, 0.17)0.859 3 to 6 months0.09 (−0.12, 0.30)−0.11 (−0.40, 0.18)0.155 6 to 12 months−0.05 (−0.27, 0.16)0.22 (−0.10, 0.54)0.064MTFJBaseline1.6 (1.1, 2.2)1.1 (0.3, 1.9)0.418Delta sum 0 to 3 months−0.11 (−0.41, 0.20)−0.11 (−0.49, 0.27)0.727 3 to 6 months−0.07 (−0.27, 0.13)0.06 (−0.21, 0.32)0.530 6 to 12 months0.07 (−0.21, 0.35)0.17 (−0.38, 0.71)0.673Delta subregion 0 to 3 months−0.07 (−0.30, 0.16)−0.17 (−0.47, 0.14)0.574 3 to 6 months−0.05 (−0.21, 0.10)0.06 (−0.21, 0.32)0.525 6 to 12 months0.02 (−0.20, 0.24)0.17 (−0.38, 0.71)0.646PFJBaseline1.0 (0.5, 1.5)1.5 (0.1, 2.9)1.000Delta sum 0 to 3 months0.05 (−0.09, 0.20)−0.06 (−0.45, 0.34)0.772 3 to 6 months−0.09 (−0.24, 0.06)0.00 (−0.24, 0.24)0.647 6 to 12 months−0.09 (−0.31, 0.13)0.06 (−0.38, 0.49)0.123Delta subregion 0 to 3 months0.05 (−0.09, 0.20)−0.06 (−0.45, 0.34)0.772 3 to 6 months−0.09 (−0.24, 0.06)0.00 (−0.24, 0.24)0.647 6 to 12 months−0.11 (−0.32, 0.10)0.06 (−0.38, 0.49)0.115*CI* confidence interval, *LTFJ* lateral tibio-femoral joint (includes 5 subregions), *MTFJ* medial tibio-femoral joint (includes 5 subregions), *PFJ* patello-femoral joint (includes 4 subregions). Possible score range for bone marrow lesion is 0--3 for each subregion at baseline, 3-, 6- and 12-month\*Statistically significant at *p* ≤ 0.05

Discussion {#Sec10}
==========

In this post-hoc analysis of the effects of sprifermin on cartilage and non-cartilaginous joint tissues, the most notable finding was that cartilage surface morphology showed less worsening from baseline to 12 months in the PFJ, and that BMLs analyzed for the whole knee showed improvement after 100 μg sprifermin treatment from 6 to 12, but not from baseline to 6 months. For other parameters, subregional analyses and observation intervals, the results were not significant, ─ possibly a consequence of small numbers, which make statistical interpretation challenging.

In light of the previous trials showing more marked treatment effects on cartilage in the lateral knee compartment as compared to the medial knee compartment \[[@CR15], [@CR16]\], it is interesting to note that in this analysis using subregional analytic approaches, a non-significant tendency toward less worsening in the lateral femorotibial compartment (LTFC) as compared to the medial femorotibial compartment (MTFC) was observed. The reasons for the seemingly preferential effect on the lateral knee compartment in the present and previous studies are still under debate. Commonly, the medial compartment is subjected to more loading and is also more severely affected by OA. Consequently, an anabolic agent acting on cartilage may be less effective in areas of mechanical challenge that are already severely damaged, such as the medial compartment.

A strong association between BMLs and cartilage surface morphology has been shown in previous work using subregional semi-quantitative approaches \[[@CR9], [@CR17]\]. While no definitive effects on BML change were seen from baseline to 12 months, more improvement of BMLs was shown from 6 to 12 months for the whole knee analysis, a finding that is not easily explained. Whether cartilage alterations may have secondary biomechanical effects on the adjacent subchondral bone, which may lead to a decrease in localized loading and regression of BMLs remains to be shown \[[@CR18]\]. Fluctuations of BMLs have been observed, focusing attention on BMLs as potential treatment targets \[[@CR3], [@CR16]\]. The finding that sprifermin may have indirect or direct effects on the subchondral bone hence warrants further exploration.

Finally, no significant changes between treatment and placebo groups were seen for other joint parameters including osteophytes, meniscal pathology, effusion, and synovitis. This may be explained by the pharmacologic mode of action of sprifermin targeting cartilage, the slow course of the disease, and the limited number of patients in each cohort.

Limitations of our post-hoc analysis include the small sample size, and therefore corresponding lack of multiple adjustment in addition to not handling of missing data. Further, we only used matched, rather than all, placebo patients for comparison with the 100 μg cohort, because this was an ascending dose escalation safety study, and in which each of the 10, 30 and 100 μg cohort were randomized and matched with a placebo control at different times throughout the study.

Conclusions {#Sec11}
===========

In summary, positive effects on the patello-femoral cartilage from baseline to 12 months and on BMLs in whole knee analyses were seen from 6 to 12 months. Continued clinical and basic studies are warranted to understand better the potential effects of sprifermin on different joint structures.
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